The presence of TILs in particular in HER2-positive and TNBC samples has been repeatedly associated with a favorable prognosis [32, 33] and, not less importantly, with an improved response to neoadjuvant cytotoxic [34, 35] and target specific [24, 36, 37] tumor treatments. This evidence concerns the gene ERBB2 and neoplasm.